Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2018 07:30 ET | Source: Dare Bioscience, Inc.

Daré Bioscience Provides Business Update and Announces Third Quarter Financial Results

SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today provided a business update and announced financial...
November 06, 2018 08:00 ET | Source: Dare Bioscience, Inc.

Daré to Host Third Quarter 2018 Financial Results Conference Call and Webcast

SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it will host a conference call and live...
October 30, 2018 08:00 ET | Source: Dare Bioscience, Inc.

Daré Announces Two Late-Breaking Abstracts to be Presented at the American Association of Pharmaceutical Scientists (AAPS) in Washington D.C.

SAN DIEGO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it will be presenting two late-breaking...
October 23, 2018 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience, Inc. to Present at the Dawson James Small Cap Growth Conference

SAN DIEGO, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that John Fair, Chief Business Officer, will...
October 15, 2018 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience, Inc. to Present an Overview of Novel Intra-Vaginal Ring (IVR) Technologies at the Partnership Opportunities in Drug Delivery (PODD) Meeting Held in Boston, MA October 17th – 18th

SAN DIEGO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s health-focused biopharmaceutical company, today announced it will be presenting...
October 10, 2018 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience, Inc. to Present at the 2018 BIO Investor Forum

SAN DIEGO, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that Sabrina Martucci Johnson, President and...
September 17, 2018 08:00 ET | Source: Dare Bioscience, Inc.

Greg Matz Joins Daré Bioscience Board of Directors

SAN DIEGO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Greg Matz to its board of...
August 30, 2018 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience, Inc. to Present at the H.C. Wainwright 20th Annual Global Investment Conference

SAN DIEGO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that John Fair, Chief Business Officer, will...
August 02, 2018 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience, Inc. to Present at the Canaccord Genuity 38th Annual Growth Conference

SAN DIEGO, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that John Fair, Chief Business Officer, will...
July 16, 2018 08:00 ET | Source: Dare Bioscience, Inc.

Daré Bioscience, Inc. Announces Asset Transfer Agreement with Hydra Biosciences, Inc. for CatSper Contraceptive Target

CatSper antagonist has potential to provide pregnancy prevention via administration to either women or men as a novel, rapidly reversible, non-hormonal contraceptive SAN DIEGO, July 16, 2018 ...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right